Biofabricated Fashion Turns Toward Reality as Scaling Challenges Mount

At FIT’s 20th annual Sustainable Business and Design Conference, the mood around biofabricated fashion had shifted from breathless promise to hard-nosed reality. The conversation, once shaped by sweeping timelines and prototype spectacle, focused instead on the stubborn basics of getting these materials made at scale, at a price brands can live with, and with performance that holds up in the real world.

The April 8 to 9, 2026 conference in New York City, themed Industry Disruptors, marked 20 years of the Sustainable Business and Design series, which began in 2007. Onstage, longtime biomaterials pioneer Suzanne Lee, who founded Biofabricate, represented a field that has grown more disciplined with age. The new language is not about fantasy materials arriving overnight. It is about whether biofabricated leather, lab-grown fibers and other next-gen textiles can survive procurement meetings, factory constraints and season-after-season wear.

That recalibration matters because the sector’s biggest obstacles are now plain. Boston Consulting Group says scaling next-generation materials is hindered by financial, technical and operational barriers, and Fashion for Good puts the market in blunt terms: next-gen materials are about 1% of the fiber market today. The same analysis says they could reach 8% by 2030, or roughly 13 million tons, if adoption accelerates. Getting there will require more than optimistic press releases. Brands need consistent demand signals, pooled demand and transition financing if these materials are going to move from niche to norm.

The clearest sign of progress is that commercialization is no longer theoretical. MycoWorks said its 136,000-square-foot fine-mycelium plant in Union, South Carolina began production on Sept. 20, 2023, and was built to supply luxury partners with millions of square feet of Reishi each year. Modern Meadow is also positioning its biofabricated leather alternatives for commercial-scale use. Those are meaningful steps, but they also underline the distance between a successful sample and a reliable industrial pipeline.

Biofabricate has framed the sector as more mature than in its earlier Wild West phase, and Lee has said success now means contracts signed and biomaterials embedded in supply chains. That is the real post-hype test for the category: not whether biofabricated fashion can make headlines, but whether mills, buyers and manufacturers can make it repeatable.